• Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC
  • DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States
  • LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB
  • LevelJump Healthcare is a national medical diagnostic imaging company providing radiology support to hospitals, emergency rooms and private clinics
  • LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET

Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC. 

DTC is a subsidiary of the Depository Trust & Clearing Corp. (DTCC) that manages the electronic clearing and settlement of publicly-traded companies in the United States.

LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB.

Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States.

Mitch Geisler, CEO commented on the benefits of DTC eligibility.

“With DTC eligibility, our shares will be more accessible to a broader range of investors in the U.S. This should allow LevelJump to increase its global shareholder base and increase the liquidity of our common shares to the benefit of all investors.” 

LevelJump Healthcare is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers.

LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.